Verastem, Inc. is a biopharmaceutical company dedicated to discovering and bringing to market new medicines that improve outcomes for patients with RAS/MAPK pathway-driven cancers. The company’s lead commercial product, AVMAPKI FAKZYNJA CO‑PACK, combines avutometinib, a dual RAF/MEK inhibitor, with defactinib, a focal adhesion kinase (FAK) inhibitor, to block both the MAPK pathway and the feedback loop that drives resistance. This combination received accelerated approval from the U. S. Food and Drug Administration on May 8, 2025, for adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer who have received prior systemic therapy. Beyond the approved therapy, Verastem’s pipeline features VS‑7375, an oral small‑molecule that inhibits both the active and inactive states of KRAS G12D, currently being evaluated in a Phase 1/2 trial (VS‑7375‑101) for pancreatic, non‑small cell lung, colorectal and other solid tumors. Earlier‑stage efforts include undisclosed assets arising from the GenFleet collaboration and ongoing preclinical work targeting additional nodes of the RAS/MAPK cascade, such as direct KRAS G12D inhibition and alternative RAF/MEK strategies.

Revenue is derived principally from sales of AVMAPKI FAKZYNJA CO‑PACK in the United States, where the product became available through specialty pharmacies within days of its May 2025 approval and generated $30.9 million of net product revenue during the first seven months of that year. In addition to product sales, Verastem receives milestone payments, royalties and research funding under its collaboration agreements; notable examples include a $6.0 million upfront payment to GenFleet Therapeutics upon exercising the option for VS‑7375, ongoing royalty obligations to Chugai for avometinib, and tiered milestones payable to Pfizer linked to the commercial performance of defactinib. These supplementary cash flows help fund the company’s clinical development programs and provide non‑dilutive support as it advances its pipeline toward later‑stage trials and potential regulatory submissions.

Within the oncology landscape, Verastem occupies a specialized niche as a developer of therapies that directly target the RAS/MAPK signaling pathway, an approach that differentiates it from broader‑spectrum cytotoxic agents. The company holds the first FDA‑approved indication for KRAS‑mutated recurrent low‑grade serous ovarian cancer, a rare disease for which no other targeted therapy had previously received clearance. Competitors in the RAF/MEK space include large pharmaceutical firms such as AbbVie, AstraZeneca, Bristol Myers Squibb, and Pfizer, each of which markets or is developing MEK or RAF inhibitors for various tumor types. In the KRAS G12D arena, rivals comprise companies like Astellas Pharma, Bayer, GenFleet, and several biotechs pursuing covalent or allosteric inhibitors of that mutation. Verastem’s competitive advantages stem from its mechanistic combination of MEK and FAK inhibition, which aims to prevent pathway reactivation and fibrosis‑mediated resistance; its early regulatory recognitions, including breakthrough therapy designation, orphan drug status in both the United States and the European Union, and fast‑track designation for VS‑7375; and a deep pipeline that couples a commercial product with multiple clinical‑stage candidates addressing different points of the same signaling cascade. Furthermore, the company’s intellectual property portfolio, comprising licensed patents from Chugai, Pfizer and GenFleet, provides composition‑of‑matter and method‑of‑use protection that extends well into the 2030s for its key assets.

The company serves physicians and patients in the United States who treat or are affected by RAS/MAPK‑driven malignancies, delivering its approved product primarily through a network of specialty pharmacies and specialty distributors that service oncology clinics and hospital‑based cancer centers. While specific customer names are not disclosed in the filing, the user base encompasses academic medical centers, community oncology practices, and integrated health‑system providers that manage recurrent low‑grade serous ovarian cancer and, in ongoing clinical studies, patients with pancreatic, non‑small cell lung, and colorectal cancers harboring KRAS G12D mutations. Verastem also offers patient‑support services, including assistance with insurance navigation and access programs, to help ensure that eligible individuals can obtain and remain on therapy. This focus on both prescriber facilitation and patient access underpins its commercial strategy in a rare‑disease setting where awareness and reimbursement guidance are critical.